Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO NASDAQ:BPMC NASDAQ:IBRX NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$49.09+1.8%$43.92$21.72▼$49.77$9.38B1.233.05 million shs2.14 million shsBPMCBlueprint Medicines$129.46$128.74$73.04▼$129.65$8.36B0.891.55 million shsN/AIBRXImmunityBio$2.47$2.78$1.83▼$7.48$2.33B0.127.67 million shs7.46 million shsVRNAVerona Pharma PLC American Depositary Share$105.190.0%$97.62$23.79▼$105.50$8.95B0.122.31 million shs1.97 million shs10 Stocks Set to Soar in Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma+3.56%+1.03%+3.81%+45.04%+97.46%BPMCBlueprint Medicines0.00%0.00%+0.12%+30.24%+37.87%IBRXImmunityBio+1.23%+2.49%-12.10%-1.59%-45.59%VRNAVerona Pharma PLC American Depositary Share-0.04%-0.22%+0.39%+55.75%+365.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBIOBridgeBio Pharma4.7166 of 5 stars4.53.00.03.93.03.30.6BPMCBlueprint Medicines0.6447 of 5 stars2.12.00.00.00.00.80.6IBRXImmunityBio1.99 of 5 stars3.61.00.00.01.71.70.6VRNAVerona Pharma PLC American Depositary Share1.5627 of 5 stars2.13.00.00.01.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 3.00Buy$61.3524.98% UpsideBPMCBlueprint Medicines 2.11Hold$130.000.42% UpsideIBRXImmunityBio 3.20Buy$12.25395.95% UpsideVRNAVerona Pharma PLC American Depositary Share 2.15Hold$109.003.62% UpsideCurrent Analyst Ratings BreakdownLatest IBRX, VRNA, BBIO, and BPMC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/6/2025BBIOBridgeBio PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$55.00 ➝ $57.008/6/2025BBIOBridgeBio PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $61.008/5/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.007/30/2025BBIOBridgeBio PharmaRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$56.007/29/2025BBIOBridgeBio PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$95.007/25/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.007/21/2025BBIOBridgeBio PharmaTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$66.007/14/2025BBIOBridgeBio PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $68.007/14/2025BBIOBridgeBio PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.007/14/2025VRNAVerona Pharma PLC American Depositary ShareHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$90.00 ➝ $107.007/11/2025BBIOBridgeBio PharmaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$58.00 ➝ $67.00(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$221.90M42.29N/AN/A($7.71) per share-6.37BPMCBlueprint Medicines$562.12M14.87N/AN/A$4.70 per share27.54IBRXImmunityBio$14.74M158.40N/AN/A($0.57) per share-4.33VRNAVerona Pharma PLC American Depositary Share$42.28M211.80N/AN/A$2.56 per share41.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$4.09N/AN/AN/A-329.25%N/A-85.69%N/ABPMCBlueprint Medicines-$67.09M-$2.47N/A199.17N/A-27.70%-64.60%-17.22%10/28/2025 (Estimated)IBRXImmunityBio-$413.56M-$0.48N/AN/AN/A-648.57%N/A-113.86%N/AVRNAVerona Pharma PLC American Depositary Share-$173.42M-$0.99N/A3,506.33N/A-36.62%-21.12%-9.07%8/14/2025 (Estimated)Latest IBRX, VRNA, BBIO, and BPMC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share$0.39N/AN/AN/A$68.24 millionN/A8/6/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share-$0.01$0.13+$0.14$0.13$90.41 million$103.14 million8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 million8/5/2025Q2 2025IBRXImmunityBio-$0.10-$0.10N/A-$0.10$21.95 million$26.43 million5/12/2025Q1 2025IBRXImmunityBio-$0.12-$0.15-$0.03-$0.15$17.50 million$16.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/ABPMCBlueprint MedicinesN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A5.195.08BPMCBlueprint Medicines1.012.802.75IBRXImmunityBioN/A4.113.98VRNAVerona Pharma PLC American Depositary Share0.8710.7110.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%BPMCBlueprint MedicinesN/AIBRXImmunityBio8.58%VRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%BPMCBlueprint Medicines4.21%IBRXImmunityBio76.79%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400191.17 million156.38 millionOptionableBPMCBlueprint Medicines64064.58 million61.86 millionOptionableIBRXImmunityBio590945.26 million219.39 millionOptionableVRNAVerona Pharma PLC American Depositary Share3085.13 million81.05 millionOptionableIBRX, VRNA, BBIO, and BPMC HeadlinesRecent News About These CompaniesAll You Need to Know About Verona Pharma (VRNA) Rating Upgrade to Buy5 hours ago | zacks.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) is Knott David M Jr's 8th Largest PositionAugust 12 at 8:17 AM | marketbeat.comVerona Pharma PLC American Depositary Share (VRNA) Expected to Announce Quarterly Earnings on ThursdayAugust 12 at 2:21 AM | americanbankingnews.comWatchtower Advisors LP Reduces Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)August 9 at 8:03 AM | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) is Vivo Capital LLC's 2nd Largest PositionAugust 9 at 7:11 AM | marketbeat.comVerona Pharma PLC American Depositary Share (VRNA) to Release Earnings on ThursdayAugust 7, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director James Aloysius Brady Sells 824 SharesAugust 6, 2025 | marketbeat.comInsider Selling: Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director Sells 1,808 Shares of StockAugust 6, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director Sells $25,018.56 in StockAugust 6, 2025 | marketbeat.comInsider Selling: Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director Sells 3,608 Shares of StockAugust 6, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director Vikas Sinha Sells 4,328 SharesAugust 6, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director Sells $124,356.96 in StockAugust 6, 2025 | marketbeat.comInsider Selling: Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Sells 9,584 Shares of StockAugust 6, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director Sells $142,017.12 in StockAugust 6, 2025 | marketbeat.comMartin Edwards Sells 10,808 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) StockAugust 6, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director Sells $148,324.32 in StockAugust 6, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Insider Kathleen A. Rickard Sells 58,336 SharesAugust 6, 2025 | marketbeat.comInsider Selling: Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) CEO Sells 208,912 Shares of StockAugust 6, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) CFO Mark W. Hahn Sells 208,912 SharesAugust 6, 2025 | marketbeat.comJames Aloysius Brady Sells 824 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) StockAugust 6, 2025 | insidertrades.comBIT Capital GmbH Sells 26,423 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)August 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIBRX, VRNA, BBIO, and BPMC Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$49.09 +0.85 (+1.76%) Closing price 04:00 PM EasternExtended Trading$47.75 -1.34 (-2.73%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Blueprint Medicines NASDAQ:BPMC$129.46 0.00 (0.00%) As of 07/18/2025Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.ImmunityBio NASDAQ:IBRX$2.47 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.50 +0.02 (+1.01%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$105.19 -0.05 (-0.05%) Closing price 04:00 PM EasternExtended Trading$104.80 -0.39 (-0.37%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AST SpaceMobile on Track for Explosive Upside Oklo’s Stock Is Set up for a Correction—Buy It When It Bounces Alphabet Reclaims $200 Threshold—Bull Run Reignited? Apple & Trump: $100B Investment, Tariffs News Push Shares Up 13% How Vertiv Is Cashing in on AI's Power Crisis CrowdStrike Faces Valuation Test Before Key Earnings Report AMD Paves Path for Market Share Gains: Stock Rally Has Just Begun Post-Earnings, How Does D-Wave Stack Up Against Quantum Rivals? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access